Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection.
- Resource Type
- article
- Source
- PLoS ONE, Vol 10, Iss 10, p e0140623 (2015)
- Subject
Medicine Science - Language
- English
- ISSN
- 1932-6203